

### August 5, 2015

I, the undersigned, Chief Financial Officer do hereby certify as follows:

- 1) I have reviewed the financial statements, and other financial information included with the financial statements, of Halifax Health and Halifax Medical Center Restricted Group as of and for the nine months ended June 30, 2015.
- 2) To the best of my knowledge, these financial statements and other financial information included with the financial statements do not contain an untrue statement of material fact and fairly present in all material respects the financial condition and results of operations as of, and for, the periods presented.
- 3) I am responsible for establishing and maintaining procedures that ensure that material information relating to the company is made known to us by others, particularly during the periods presented.
- 4) I have disclosed to the external auditors and the Audit Committee of the Board of Commissioners:
  - all significant deficiencies in the design or operation of internal controls which could adversely affect the ability to record, process, summarize and report financial data and have identified for the auditors any material weaknesses in internal controls;
  - b. any fraud, whether or not material, that involves management or other employees who have a significant role in internal controls.
- 5) I have determined that there were no significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Eric M. Peburn

Chief Financial Officer

HALIFAX HEALTH MEDICAL CENTER 303 N. CLYDE MORRIS BIA'D. DAYTONA BEACH, FL 32114

T: 386.254.4000

halifaxhealth.org

## Halifax Health Summary Financial Narrative For the nine months ended June 30, 2015

The year-to-date operating performance of Halifax Health (HH) is at or above budgeted targets, except for the debt to capitalization ratio that is expected to move to the budgeted target by fiscal year-end. HH's year-to-date performance compared to budget for key financial indicators is as follows

Financial Indicator	YTD Actual FY15
Total Margin	5.1%
Operating Margin	3.8%
EBIDA Margin	13.3%
Days Cash on Hand	278
Cash to Debt	99.1%
Debt to Capitalization	58.6%

YTD Budget FY15	YTD Actual vs. Budget
4.7%	Favorable
3.2%	Favorable
13.2%	Favorable
266	Favorable
96.6%	Favorable
58.0%	Unfavorable

OG MADS Coverage	2.67	
OG Debt to Capitalization	58.8%	

2.39	Favorable
58.5%	Unfavorable

#### Halifax Health Medical Center

Statistical Summary--

- Admissions for the month are greater than budget and last year; and for the year-to-date are less than budget and last year.
- Patient days for the month are greater than budget and less than last year; and for the year-to-date are
  greater than budget and last year.
  - o Observation patient day equivalent units for the month are less than budget and last year; and for the year-to-date are greater than budget and last year.
- Surgery volumes for the month and year to date are greater than budget and last year.
- Emergency Room visits for the month are greater than budget and less than last year; and for the year-to-date are greater than budget and last year.

#### Financial Summary --

- Net patient service revenue for the year-to-date is 3.9% greater than budget.
- Total operating expenses for the year-to-date are 2.2% greater than budget.
- Income from operations year-to-date of \$12.7 million compares favorably to budget by \$5.0 million.
- Nonoperating gains year-to-date of \$1.8 million, primarily consisting of investment income of \$3.1 million and bond issuance costs of \$1.4 million, is less than the budgeted amount by \$598,000.
- The increase in net position year-to-date of \$14.5 million compares favorably to budget by \$4.4 million.

#### **Halifax Health Hospice**

Statistical Summary -

• Patient days for the month and year-to-date are less than budget and greater than last year.

#### Financial Summary --

- Net patient service revenue for the year-to-date is 13.8% less than budget.
- Loss from operations year-to-date of \$2.6 million compares unfavorably to budget by \$3.5 million.
- Nonoperating gains year-to-date of \$3.5 million, including investment income of \$2.8 million, is less than the budgeted amount by \$51,000.
- The increase in net position year-to-date of \$891,000 compares unfavorably to budget by \$3.6 million.

Other Component Units - The year-to-date financial performance is materially consistent with budgeted expectations.

### Halifax Hospital Medical Center Historical Utilization

Fiscal Year Ended September 30,   June 30,   2012   2013   2014   2015
<u>Inpatient Activity:</u> Admissions 22,770 22,321 22,381 16,826
Admissions 22,770 22,321 22,381 16,826
Admissions 22,770 22,321 22,381 16,826
10,020
Patient Days 117,493 119,833 124,296 98,138
Available Beds 541 533 526 533
Average Percent Occupancy 59.3% 61.6% 64.7% 67.4%
Average Length of Stay (Days) 5.2 5.4 5.6 5.8
Average Daily Census 321 328 341 359
Inpatient Admissions and
Observation Patients 32,380 31,468 31,282 23,146
Outpatient Activity:
Oncology Visits 48,491 49,684 48,891 37,237
Other Outpatient Visits 83,624 74,766 68,440 48,983
Community Clinic Visits 19,090 17,378 13,470 12,881
Primary Care and Children's Clinic Visits 0 0 16,375 20,668
Emergency Department <u>116,850</u> <u>112,576</u> <u>113,477</u> <u>86,923</u>
Total 268,055 254,404 260,653 206,692
Surgical Activity:
Inpatient 5,408 5,253 4,995 3,811
Outpatient <u>11,000</u> <u>10,628</u> <u>10,065</u> <u>7,760</u>
Total 16,408 15,881 15,060 11,571

## Halifax Hospital Medical Center Sources of Payment

	Nine-Months Ended June 30,			
	<u>2012</u>	<u>2013</u>	2014	<u>2015</u>
Payment Source:				
HMO/PPO	18.8%	18.8%	21.1%	23.2%
Medicare <sup>(1)</sup>	44.0%	42.2%	39.9%	39.7%
Commercial/Other	23.5%	23.4%	22.1%	23.3%
Medicaid <sup>(2)</sup>	13.0%	14.9%	16.4%	13.3%
Uninsured	0.7%	0.7%	0.5%	0.5%
Total	100.0%	100.0%	100.0%	100.0%

<sup>(1)</sup> Includes Medicare/Medicare HMO reimbursement

<sup>(2)</sup> Includes Medicaid/Meidcaid HMO reimbursement

# Halifax Hospital Medical Center (Obligated Group) Statements of Net Position (\$ in thousands)

	2012	eptember 30, <u>2013</u>	2014	June 30, <u>2015</u>
Assets and Deferred Outflows				
Current Assets	****	405.565	450 500	410.000
Cash and cash equivalents	\$30,417	\$35,765	\$52,509	\$42,230
Investments	161,105	161,209	163,769	174,273
Current assests whose use is limited, trustee-held self insurance funds	881	806	734	716
Accounts receivable-patients, net	40,967	43,514	48,528	55,168
Inventories	11,312	11,365	11,439	12,424
Other current assets	11,574	16,140	15,076	10,861
Total current assets	256,256	268,799	292,055	295,672
Restricted funds under indenture agreements for debt service	20,452	20,196	20,196	20,058
Noncurrent assets whose use is limited:				
Board-designated funded depreciation	167,172	147,258	41,105	41,480
Capital assets, at cost, net	337,792	340,918	332,502	325,682
Investment in affiliates	95,277	113,077	114,647	119,857
Other assets	11,006	13,482	13,846	13,160
Total assets	887,955	903,730	814,351	815,909
Deferred outflows:				
Interest rate swap	33,398	19,262	24,531	27,744
Pension contribution after measurement(1)	0	0	18,970	12,816
Bond issue costs (1)	9,630	9,282	0	0
Loss on refunding of debt	5,028	4,664	2,078	6,790
Total deferred outflows	48,056	33,208	45,579	47,350
Total assets and deferred outflows	\$936,011	\$936,938	\$859,930	\$863,259
Liabilities, Deferred Inflows and Net Position				
Current liabilities:				
Accounts payable and accrued liabilities	\$58,140	\$61,496	\$65,617	\$69,750
Current portion of accrued self-insurance liability	5,233	5,001	4,786	4,198
Current portion of long-term debt	1,830	1,855	3,155	3,205
Other current liabilities	6,167	8,858	7,892	7,520
Total current liabilities	71,370	77,210	81,450	84,673
Long-term debt, less current portion	346,762	344,922	341,784	347,161
Accrued self-insurance liability, less current portion	7,647	8,268	8,792	8,490
Deferred inflows related to pension (1)	0	0	40,176	23,589
Net pension liability (1)	0	0	113,647	105,160
Other long-term liabilities	11,866	11,535	23,065	20,248
Long-term value of swap	33,398	19,262	24,531	27,744
Net position (1)	464,968	475,741	226,485	246,194
Total liabilities, deferred inflows and net position	\$936,011	\$936,938	\$859,930	\$863,259
- vine amounted, account and one and the popular	+	4.30,700	1//-	+500/25/

Note:

<sup>(1)</sup> Halifax Health implemented GASB 65 and GASB 68 as of October 1, 2013.

## Halifax Hospital Medical Center (Obligated Group) Statements of Revenues, Expenses and Changes in Net Position (\$ in thousands)

	Year End	led Septemb	er 30.	Nine-Months Ended June 30
	2012	2013	2014	<u>2015</u>
Operating revenues:				
Net patient service revenue - before provision for bad debts	\$484,257	\$479,925	\$501,464	\$396,099
Provision for bad debts	(98,128)	(93,727)	(96,815)	(79,705)
Net patient service revenue	386,129	386,198	404,649	316,394
Ad valorem tax revenue	21,934	15,273	12,465	9,862
Other revenue	17,512	17,555	17,386	13,351
Total operating revenues	425,575	419,026	434,500	339,607
Operating expenses:				
Salaries and benefits	222,451	215,744	202,726	158,268
Purchased services (2)	41,652	41,761	50,084	45,752
Supplies	79,455	82,235	80,437	63,919
Depreciation and amortization	19,343	19,863	21,119	16,558
Ad valorem tax related expenses	9,091	6,685	6,750	5,150
Leases and rentals	8,297	8,015	7,817	5,581
Other	23,826	25,251	24,809	18,070
Total operating expenses	404,115	399,554	393,742	313,298
Income from operations before Settlements and related costs	21,460	19,472	40,758	26,309
Settlements and related costs (2)	(5,698)	(8,545)	(106,435)	0
Income (loss) from operations	15,762	10,927	(65,677)	26,309
Nonoperating revenues, expenses, and gains (losses):				
Interest expense	(18,905)	(18,561)	(18,325)	(14,957)
Investment income, net	13,472	472	5,730	3,126
Donation revenue	607	80	407	45
Nonoperating gains (losses), net	(293)	55	896	(24)
Income from affiliates	18,211	17,800	11,018	5,210
Total nonoperating revenues, expenses, and gains (losses)	13,092	(154)	(274)	(6,600)
Increase (decrease) in net position before other changes in net position	28,854	10,773	(65,951)	19,709
Other changes in net position:				
Change in accounting - pension (1)	0	0	(171,281)	0
Change in accounting - bond issue costs (1)	0	0	(12,024)	0
Total other changes in net position:	0	0	(183,305)	0
Increase (degrees) in put position	\$28,854	\$10,773	(\$249,256)	\$19,709
Increase (decrease) in net position	φ40,034	φ10,//3	(ΦΔ47,200)	\$19,709

 $<sup>^{\</sup>rm (1)}$  Halifax Health implemented GASB 65 and GASB 68 as of October 1, 2013.

<sup>(2)</sup> Litigation costs related to the Settlements for the fiscal years ended September 30, 2012 and 2013 have been reclassified from purchased services to Settlements and related costs to conform with the fiscal year 2014 presentation.

## Halifax Health Statements of Net Position (\$ in thousands)

	September 30,			June 30,
	2012	2013	2014	2015
Assets and Deferred Outflows				
Current Assets				
Cash and cash equivalents	\$31,290	\$37,238	\$93,366	\$43,682
Investments	226,112	242,784	212,908	266,024
Current assests whose use is limited, trustee-held self insurance funds	881	806	734	716
Accounts receivable-patients, net	45,504	47,186	52,521	59,983
Inventories	11,427	11,459	11,561	12,546
Other current assets	11,722	16,245	15,159	10,989
Total current assets	326,936	355,718	386,249	393,940
Restricted funds under indenture agreements for debt service	20,660	20,404	20,386	25,914
Noncurrent assets whose use is limited:				
Board-designated	169,822	149,908	43,755	38,459
Other	5,675	5,671	5,671	5,671
Capital assets, at cost, net	373,723	376,494	369,118	363,785
Other assets	15,086	17,371	18,105	14,691
			57/, 141	
Total assets	911,902	925,566	843,284	842,460
Deferred outflows:				
Interest rate swap	33,398	19,262	24,531	27,744
Pension contribution after measurement (1)	0	0	20,000	13,512
Bond issue costs (1)	9,768	9,395	0	0
Loss on refunding of debt	5,416	4,982	2,143	6,841
Total deferred outflows	48,582	33,639	46,674	48,097
Total assets and deferred outflows	\$960,484	\$959,205	\$889,958	\$890,557
Liabilities, Deferred Inflows and Net Position				
Current liabilities:		*****		1#10uthampin
Accounts payable and accrued liabilities	\$60,465	\$63,304	\$68,338	\$72,782
Current portion of accrued self-insurance liability	5,233	5,001	4,786	4,198
Current portion of long-term debt Other current liabilities	3,912 8,467	4,006 11,039	5,375 9,894	5,470
Total current liabilities	78,077	83,350	88,393	7,554 90,004
				134.0000 1450.0010
Long-term debt, less current portion	357,182	353,192	347,834	351,509
Accrued self-insurance liability, less current portion	7,647	8,268	8,792	8,490
Deferred inflows - related to pension (1)	0	0	42,357	24,935
Net pension liability (1)	0	0	119,818	111,190
Other long-term liabilities	13,358	13,538	25,894	24,636
Long-term value of swap	33,398	19,262	24,531	27,744
Net position (1)	470,822	481,595	232,339	252,049
Total liabilities, deferred inflow and net position	\$960,484	\$959,205	\$889,958	\$890,557

Note

<sup>(1)</sup> Halifax Health implemented GASB 65 and GASB 68 as of October 1, 2013.

# Halifax Health Statements of Revenues, Expenses and Changes in Net Position (\$ in thousands)

				Nine-Months	
	Year Ended September 30,			Ended June 31,	
	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	
Operating revenues:					
Net patient service revenue - before provision for bad debts	\$531,392	\$527,333	\$543,009	\$428,261	
Provision for bad debts	(98,689)	(94,535)	(97,569)	(80,366)	
Net patient service revenue	432,703	432,798	445,440	347,895	
Ad valorem tax revenue	21,934	15,273	12,465	9,862	
Other revenue	29,198	28,854	28,117	21,864	
Total operating revenues	483,835	476,925	486,022	379,621	
Operating expenses:					
Salaries and benefits	247,626	240,008	225,224	177,371	
Purchased services (2)	55,343	55,945	64,216	56,678	
Supplies	82,316	85,475	83,584	66,610	
Depreciation and amortization	20,749	21,257	22,507	17,672	
Ad valorem tax related expenses	9,091	6,685	6,750	5,150	
Leases and rentals	10,042	9,962	9,788	7,429	
Other	27,600	28,448	28,252	20,438	
Total operating expenses before Settlements and related costs	452,767	447,780	440,321	351,348	
Income from operations before Settlements and related costs	31,068	29,145	45,701	28,273	
Settlements and related costs (2)	(5,698)	(8,545)	(106,435)	0	
Income (loss) from operations	25,370	20,600	(60,734)	28,273	
Nonoperating revenues, expenses, and gains (losses)					
Interest expense	(19,416)	(19,004)	(18,650)	(15,161)	
Investment income, net	21,182	7,828	10,853	5,877	
Donation revenue	2,017	1,306	1,684	743	
Nonoperating gains (losses), net	(299)	43	896	(23)	
Total nonoperating revenues, expenses, and gains (losses)	3,484	(9,827)	(5,217)	(8,564)	
Increase (decrease) in net position before other changes in net					
position	28,854	10,773	(65,951)	19,709	
Other changes in net position:					
Change in accounting - pension (1)	0	0	(171,281)	0	
Change in accounting - bond issue costs (1)	0	0	(12,024)	0	
Total other changes in net position	0	0	(183,305)	0	
Increase (decrease) in net position	\$28,854	\$10,773	(\$249,256)	\$19,709	
-					

<sup>(1)</sup> Halifax Health implemented GASB 65 and GASB 68 as of October 1, 2013.

<sup>(2)</sup> Litigation costs related to the Settlements for the fiscal years ended September 30, 2012 and 2013 have been reclassified from purchased services to Settlements and related costs to conform with the fiscal year 2014 presentation.

## Halifax Health Statements of Cash Flows (\$ in thousands)

Cash flows from operating activities:         2012         2013         2014         2015           Cash flows from operating activities:         8429,847         \$441,413         \$440,285         \$362,084           Payments to employees         (248,909)         (244,616)         (240,649)         (186,410)           Payments to suppliers         (144,342)         (159,315)         (153,093)         (142,828)           Receipt of ad valorem taxes         21,934         15,182         18,471         12,983           Other receipts         24,996         29,078         26,895         15,544           Other payments         (45,802)         (44,367)         (144,725)         (33,073)           Net cash provided by (used in) operating activities:         37,124         37,375         (52,816)         28,210           Cash flows from noncapital financing activities:           Payments for acquisition of a business         0         0         (185,00         0           Payment for acquisition of a business         0         0         0         0           Payment for acquisition of a business         0         0         0         0           Payment of interest on notes payable         (456)         0         0 </th <th></th> <th>Fiscal Year</th> <th>Ended Septem</th> <th>ber 30,</th> <th>Nine-Months Ended June 30,</th>		Fiscal Year	Ended Septem	ber 30,	Nine-Months Ended June 30,
Receipts from third party payors and patients         \$429,847         \$441,413         \$440,285         \$362,084           Payments to employees         (248,090)         (244,616)         (240,649)         (186,410)           Payments to suppliers         (144,342)         (159,315)         (133,093)         (142,828)           Receipt of ad valorem taxes         21,934         15,182         18,471         12,893           Other receipts         24,396         29,078         26,895         15,544           Other payments         (45,802)         (44,367)         (144,725)         (33,073)           Net cash provided by (used in) operating activities         37,124         37,375         (52,816)         28,210           Cash flows from noncapital financing activities:           Payments for acquisition of a business         0         0         (185)         0           Purchase of equity interest         (456)         0         0         0         0           Proceeds from donations received         2,019         1,306         1,687         740           Payment of interest on notes payable         (28)         0         0         0           Other nonoperating (payments) receipts         (286)         54         18 <td< th=""><th></th><th></th><th></th><th></th><th>A SHARE SHOULD S</th></td<>					A SHARE SHOULD S
Receipts from third party payors and patients         \$429,847         \$441,413         \$440,285         \$362,084           Payments to employees         (248,090)         (244,616)         (240,649)         (186,410)           Payments to suppliers         (144,342)         (159,315)         (133,093)         (142,828)           Receipt of ad valorem taxes         21,934         15,182         18,471         12,893           Other receipts         24,396         29,078         26,895         15,544           Other payments         (45,802)         (44,367)         (144,725)         (33,073)           Net cash provided by (used in) operating activities         37,124         37,375         (52,816)         28,210           Cash flows from noncapital financing activities:           Payments for acquisition of a business         0         0         (185)         0           Purchase of equity interest         (456)         0         0         0         0           Proceeds from donations received         2,019         1,306         1,687         740           Payment of interest on notes payable         (28)         0         0         0           Other nonoperating (payments) receipts         (286)         54         18 <td< td=""><td>Cash flows from operating activities:</td><td></td><td></td><td></td><td></td></td<>	Cash flows from operating activities:				
Payments to employees		\$429,847	\$441,413	\$440,285	\$362.084
Payments to suppliers   (144,342)   (159,315)   (153,093)   (142,828)     Receipt of ad valorem taxes   21,934   15,182   18,471   12,893     Other receipts   24,396   29,078   26,895   15,544     Other payments   (45,802)   (44,367)   (144,725)   (33,073)     Net cash provided by (used in) operating activities   37,124   37,375   (52,816)   28,210     Cash flows from noncapital financing activities:   Payments for acquisition of a business   0   0   (185)   0     Purchase of equity interest   (456)   0   0   0   0     Purchase of equity interest   (456)   1,360   1,687   740     Payment of interest on notes payable   (28)   0   0   0   0     Other nonoperating (payments) receipts   (286)   54   18   (26)     Net cash provided by noncapital financing activities   1,249   1,360   1,520   714     Cash flows from capital and related financing activities   1,249   1,360   1,520   714     Cash flows from capital and related financing activities   1,249   1,360   1,520   714     Cash flows from capital and related financing activities   1,249   1,360   1,520   714     Cash flows from capital and related financing activities   1,249   1,360   1,520   714     Cash flows from capital and related financing activities   1,249   1,360   1,520   714     Cash flows from capital and related financing activities   1,249   1,360   1,520   714     Cash flows from inspective debt   (3,730)   (3,912)   (4,001)   (4,811)     Payment of long-term debt   (18,948)   (18,604)   (18,463)   (14,344)     Net cash used in capital financing activities   (34,082)   (46,231)   (38,601)   (31,764)     Cash flows from investing activities   (34,082)   (46,231)   (30,561)   (35,693)     Purchases of investments/limited use assets   87,297   125,770   341,453   3,630     Net cash provided by (used in) investing activities   (7,987)   13,444   146,025   (46,844)     Net increase (decrease) in cash and cash equivalents   34,986   31,290   37,238   93,366	The second secon		entrance (Course)	Consumer Consumer	12 12.0
Receipt of ad valorem taxes   21,934   15,182   18,471   12,893   Other receipts   24,396   29,078   26,895   15,544   Other payments   (45,802)   (44,367)   (144,725)   (33,073)     Net cash provided by (used in) operating activities   37,124   37,375   (52,816)   28,210     Cash flows from noncapital financing activities:   Payments for acquisition of a business   0   0   (185)   0   0   0   0   0   0   0   0   0				15. 4002	e
Other receipts         24,396 (45,802)         29,078 (26,895)         15,544 (33,073)           Other payments         (45,802)         (44,367)         (144,725)         (33,073)           Net cash provided by (used in) operating activities         37,124         37,375         (52,816)         28,210           Cash flows from noncapital financing activities:           Payments for acquisition of a business         0         0         (185)         0           Purchase of equity interest         (456)         0         0         0           Proceeds from donations received         2,019         1,306         1,687         740           Payment of interest on notes payable         (28)         0         0         0           Other nonoperating (payments) receipts         (286)         54         18         (26)           Net cash provided by noncapital financing activities         1,249         1,360         1,520         714           Cash flows from capital and related financing activities           Acquisition of capital assets         (14,632)         (23,715)         (16,137)         (12,609)           Proceeds from disposals         3,228         -         -         -           Payment of long-term debt         (3,730)					***************************************
Other payments         (45,802)         (44,367)         (144,725)         (33,073)           Net cash provided by (used in) operating activities         37,124         37,375         (52,816)         28,210           Cash flows from noncapital financing activities:         0         0         (185)         0           Purchase of equity interest         (456)         0         0         0           Proceeds from donations received         2,019         1,306         1,687         740           Payment of interest on notes payable         (28)         0         0         0         0           Other nonoperating (payments) receipts         (286)         54         18         (26)           Net cash provided by noncapital financing activities         1,249         1,360         1,520         714           Cash flows from capital and related financing activities:         3,228         -         -         -           Acquisition of capital assets         (14,632)         (23,715)         (16,137)         (12,609)           Proceeds from disposals         3,228         -         -         -           Payment of long-term debt         (3,730)         (3,912)         (4,001)         (4,811)           Payment of interest on long-term debt         (1	AND THE PROPERTY OF THE PROPER	24,396	29,078	26,895	A CONTRACTOR AND A CONTRACTOR
Cash flows from noncapital financing activities:           Payments for acquisition of a business         0         0         (185)         0           Purchase of equity interest         (456)         0         0         0           Proceeds from donations received         2,019         1,306         1,687         740           Payment of interest on notes payable         (28)         0         0         0           Other nonoperating (payments) receipts         (286)         54         18         (26)           Net cash provided by noncapital financing activities         1,249         1,360         1,520         714           Cash flows from capital and related financing activities:         3,228         -         -         -         -           Acquisition of capital assets         (14,632)         (23,715)         (16,137)         (12,609)         1,260         1,260         1,260         1,260         1,260         1,2609         1,260         1,260         1,260         1,260         1,2609         1,260         1,2609         1,260         1,2609         1,2609         1,260         1,2609         1,2609         1,2609         1,2609         1,2609         1,2609         1,2609         1,2609         1,2609         1,2609         <	•		(44,367)		
Payments for acquisition of a business         0         0         (185)         0           Purchase of equity interest         (456)         0         0         0           Proceeds from donations received         2,019         1,306         1,687         740           Payment of interest on notes payable         (28)         0         0         0           Other nonoperating (payments) receipts         (286)         54         18         (26)           Net cash provided by noncapital financing activities         1,249         1,360         1,520         714           Cash flows from capital and related financing activities:           Acquisition of capital assets         (14,632)         (23,715)         (16,137)         (12,609)           Proceeds from disposals         3,228         -         -         -           Payment of long-term debt         (3,730)         (3,912)         (4,001)         (4,811)           Payment of interest on long-term debt         (18,948)         (18,604)         (18,463)         (14,344)           Net cash used in capital financing activities         (34,082)         (46,231)         (38,601)         (31,764)           Cash flows from investing activities         (10,947)         (123,674)	Net cash provided by (used in) operating activities	37,124	37,375	(52,816)	28,210
Purchase of equity interest         (456)         0         0         0           Proceeds from donations received         2,019         1,306         1,687         740           Payment of interest on notes payable         (28)         0         0         0           Other nonoperating (payments) receipts         (286)         54         18         (26)           Net cash provided by noncapital financing activities         1,249         1,360         1,520         714           Cash flows from capital and related financing activities:         3,228         -         -         -           Acquisition of capital assets         (14,632)         (23,715)         (16,137)         (12,609)           Proceeds from disposals         3,228         -         -         -           Payment of long-term debt         (3,730)         (3,912)         (4,001)         (4,811)           Payment of interest on long-term debt         (18,948)         (18,604)         (18,463)         (14,344)           Net cash used in capital financing activities         (34,082)         (46,231)         (38,601)         (31,764)           Cash flows from investing activities:         10,191         11,348         6,169         5,369           Purchases of investments/limited use assets	Cash flows from noncapital financing activities:				
Proceeds from donations received         2,019         1,306         1,687         740           Payment of interest on notes payable         (28)         0         0         0           Other nonoperating (payments) receipts         (286)         54         18         (26)           Net cash provided by noncapital financing activities         1,249         1,360         1,520         714           Cash flows from capital and related financing activities:         Acquisition of capital assets         (14,632)         (23,715)         (16,137)         (12,609)           Proceeds from disposals         3,228         -         -         -         -           Payment of long-term debt         (3,730)         (3,912)         (4,001)         (4,811)           Payment of interest on long-term debt         (18,948)         (18,604)         (18,463)         (14,344)           Net cash used in capital financing activities         (34,082)         (46,231)         (38,601)         (31,764)           Cash flows from investing activities         10,191         11,348         6,169         5,369           Purchases of investments/limited use assets         (105,475)         (123,674)         (201,597)         (55,843)           Sales/Maturities of investments/limited use assets         87,297 <td>Payments for acquisition of a business</td> <td>0</td> <td>0</td> <td>(185)</td> <td>0</td>	Payments for acquisition of a business	0	0	(185)	0
Payment of interest on notes payable         (28)         0         0         0           Other nonoperating (payments) receipts         (286)         54         18         (26)           Net cash provided by noncapital financing activities         1,249         1,360         1,520         714           Cash flows from capital and related financing activities:           Acquisition of capital assets         (14,632)         (23,715)         (16,137)         (12,609)           Proceeds from disposals         3,228         -         -         -           Payment of long-term debt         (3,730)         (3,912)         (4,001)         (4,811)           Payment of interest on long-term debt         (18,948)         (18,604)         (18,463)         (14,344)           Net cash used in capital financing activities         (34,082)         (46,231)         (38,601)         (31,764)           Cash flows from investing activities           Realized investment income         10,191         11,348         6,169         5,369           Purchases of investments/limited use assets         (105,475)         (123,674)         (201,597)         (55,843)           Sales/Maturities of investments/limited use assets         87,297         125,770         341,453         3,630 <td>Purchase of equity interest</td> <td>(456)</td> <td></td> <td>0</td> <td>0</td>	Purchase of equity interest	(456)		0	0
Other nonoperating (payments) receipts         (286)         54         18         (26)           Net cash provided by noncapital financing activities         1,249         1,360         1,520         714           Cash flows from capital and related financing activities:           Acquisition of capital assets         (14,632)         (23,715)         (16,137)         (12,609)           Proceeds from disposals         3,228         -	Proceeds from donations received	2,019	1,306	1,687	740
Net cash provided by noncapital financing activities 1,249 1,360 1,520 714  Cash flows from capital and related financing activities:  Acquisition of capital assets (14,632) (23,715) (16,137) (12,609)  Proceeds from disposals 3,228  Payment of long-term debt (3,730) (3,912) (4,001) (4,811)  Payment of interest on long-term debt (18,948) (18,604) (18,463) (14,344)  Net cash used in capital financing activities (34,082) (46,231) (38,601) (31,764)  Cash flows from investing activities:  Realized investment income 10,191 11,348 6,169 5,369  Purchases of investments/limited use assets (105,475) (123,674) (201,597) (55,843)  Sales/Maturities of investments/limited use assets 87,297 125,770 341,453 3,630  Net cash provided by (used in) investing activities (7,987) 13,444 146,025 (46,844)  Net increase (decrease) in cash and cash equivalents (3,696) 5,948 56,128 (49,684)  Cash and cash equivalents at beginning of period 34,986 31,290 37,238 93,366	Payment of interest on notes payable	(28)	0	0	0
Cash flows from capital and related financing activities:         Acquisition of capital assets       (14,632)       (23,715)       (16,137)       (12,609)         Proceeds from disposals       3,228       -       -       -         Payment of long-term debt       (3,730)       (3,912)       (4,001)       (4,811)         Payment of interest on long-term debt       (18,948)       (18,604)       (18,463)       (14,344)         Net cash used in capital financing activities       (34,082)       (46,231)       (38,601)       (31,764)         Cash flows from investing activities:       Realized investment income       10,191       11,348       6,169       5,369         Purchases of investments/limited use assets       (105,475)       (123,674)       (201,597)       (55,843)         Sales/Maturities of investments/limited use assets       87,297       125,770       341,453       3,630         Net cash provided by (used in) investing activities       (7,987)       13,444       146,025       (46,844)         Net increase (decrease) in cash and cash equivalents       (3,696)       5,948       56,128       (49,684)         Cash and cash equivalents at beginning of period       34,986       31,290       37,238       93,366	Other nonoperating (payments) receipts	(286)	54	18	(26)
Acquisition of capital assets (14,632) (23,715) (16,137) (12,609) Proceeds from disposals 3,228	Net cash provided by noncapital financing activities	1,249	1,360	1,520	714
Proceeds from disposals  Payment of long-term debt  (3,730) (3,912) (4,001) (4,811) Payment of interest on long-term debt (18,948) (18,604) (18,463) (14,344)  Net cash used in capital financing activities  (34,082) (46,231) (38,601) (31,764)  Cash flows from investing activities:  Realized investment income 10,191 11,348 6,169 5,369 Purchases of investments/limited use assets (105,475) (123,674) (201,597) (55,843) Sales/Maturities of investments/limited use assets 87,297 125,770 341,453 3,630  Net cash provided by (used in) investing activities (7,987) 13,444 146,025 (46,844)  Net increase (decrease) in cash and cash equivalents (3,696) 5,948 56,128 (49,684)	Cash flows from capital and related financing activities	s:			
Payment of long-term debt         (3,730)         (3,912)         (4,001)         (4,811)           Payment of interest on long-term debt         (18,948)         (18,604)         (18,463)         (14,344)           Net cash used in capital financing activities         (34,082)         (46,231)         (38,601)         (31,764)           Cash flows from investing activities:         Realized investment income         10,191         11,348         6,169         5,369           Purchases of investments/limited use assets         (105,475)         (123,674)         (201,597)         (55,843)           Sales/Maturities of investments/limited use assets         87,297         125,770         341,453         3,630           Net cash provided by (used in) investing activities         (7,987)         13,444         146,025         (46,844)           Net increase (decrease) in cash and cash equivalents         (3,696)         5,948         56,128         (49,684)           Cash and cash equivalents at beginning of period         34,986         31,290         37,238         93,366	Acquisition of capital assets	(14,632)	(23,715)	(16,137)	(12,609)
Payment of interest on long-term debt         (18,948)         (18,604)         (18,463)         (14,344)           Net cash used in capital financing activities         (34,082)         (46,231)         (38,601)         (31,764)           Cash flows from investing activities:         Realized investment income         10,191         11,348         6,169         5,369           Purchases of investments/limited use assets         (105,475)         (123,674)         (201,597)         (55,843)           Sales/Maturities of investments/limited use assets         87,297         125,770         341,453         3,630           Net cash provided by (used in) investing activities         (7,987)         13,444         146,025         (46,844)           Net increase (decrease) in cash and cash equivalents         (3,696)         5,948         56,128         (49,684)           Cash and cash equivalents at beginning of period         34,986         31,290         37,238         93,366	Proceeds from disposals	3,228	*	9	
Net cash used in capital financing activities       (34,082)       (46,231)       (38,601)       (31,764)         Cash flows from investing activities:       Realized investment income       10,191       11,348       6,169       5,369         Purchases of investments/limited use assets       (105,475)       (123,674)       (201,597)       (55,843)         Sales/Maturities of investments/limited use assets       87,297       125,770       341,453       3,630         Net cash provided by (used in) investing activities       (7,987)       13,444       146,025       (46,844)         Net increase (decrease) in cash and cash equivalents       (3,696)       5,948       56,128       (49,684)         Cash and cash equivalents at beginning of period       34,986       31,290       37,238       93,366	Payment of long-term debt	(3,730)	(3,912)	(4,001)	(4,811)
Cash flows from investing activities:         Realized investment income       10,191       11,348       6,169       5,369         Purchases of investments/limited use assets       (105,475)       (123,674)       (201,597)       (55,843)         Sales/Maturities of investments/limited use assets       87,297       125,770       341,453       3,630         Net cash provided by (used in) investing activities       (7,987)       13,444       146,025       (46,844)         Net increase (decrease) in cash and cash equivalents       (3,696)       5,948       56,128       (49,684)         Cash and cash equivalents at beginning of period       34,986       31,290       37,238       93,366	Payment of interest on long-term debt	(18,948)	(18,604)	(18,463)	(14,344)
Realized investment income         10,191         11,348         6,169         5,369           Purchases of investments/limited use assets         (105,475)         (123,674)         (201,597)         (55,843)           Sales/Maturities of investments/limited use assets         87,297         125,770         341,453         3,630           Net cash provided by (used in) investing activities         (7,987)         13,444         146,025         (46,844)           Net increase (decrease) in cash and cash equivalents         (3,696)         5,948         56,128         (49,684)           Cash and cash equivalents at beginning of period         34,986         31,290         37,238         93,366	Net cash used in capital financing activities	(34,082)	(46,231)	(38,601)	(31,764)
Purchases of investments/limited use assets       (105,475)       (123,674)       (201,597)       (55,843)         Sales/Maturities of investments/limited use assets       87,297       125,770       341,453       3,630         Net cash provided by (used in) investing activities       (7,987)       13,444       146,025       (46,844)         Net increase (decrease) in cash and cash equivalents       (3,696)       5,948       56,128       (49,684)         Cash and cash equivalents at beginning of period       34,986       31,290       37,238       93,366	Cash flows from investing activities:				
Sales/Maturities of investments/limited use assets 87,297 125,770 341,453 3,630  Net cash provided by (used in) investing activities (7,987) 13,444 146,025 (46,844)  Net increase (decrease) in cash and cash equivalents (3,696) 5,948 56,128 (49,684)  Cash and cash equivalents at beginning of period 34,986 31,290 37,238 93,366	Realized investment income	10,191	11,348	6,169	5,369
Net cash provided by (used in) investing activities (7,987) 13,444 146,025 (46,844)  Net increase (decrease) in cash and cash equivalents (3,696) 5,948 56,128 (49,684)  Cash and cash equivalents at beginning of period 34,986 31,290 37,238 93,366	Purchases of investments/limited use assets	(105,475)	(123,674)	(201,597)	(55,843)
Net increase (decrease) in cash and cash equivalents (3,696) 5,948 56,128 (49,684)  Cash and cash equivalents at beginning of period 34,986 31,290 37,238 93,366	Sales/Maturities of investments/limited use assets	87,297	125,770	341,453	3,630
Cash and cash equivalents at beginning of period 34,986 31,290 37,238 93,366	Net cash provided by (used in) investing activities	(7,987)	13,444	146,025	(46,844)
	Net increase (decrease) in cash and cash equivalents	(3,696)	5,948	56,128	(49,684)
	Cash and cash equivalents at beginning of period	34,986	31,290	37,238	93,366
		\$31,290	\$37,238	\$93,366	\$43,682